News summarySEC EDGARNov 4, 2026, 12:00 PM
Relay Therapeutics files Q3 2026 Form 10-Q
Filed Nov. 4 for the quarter ended Sept. 30: Relay reported $848.6M in cash, equivalents and investments and $238.7M net loss for the first nine months of 2026. It said it had sold 16,006,569 shares through its ATM for $159.2M net proceeds as of Sept. 30; the ATM program was increased to $463M in August 2026.